PANCREATIC CANCER

Modified FOLFIRINOX superior to gemcitabine in resected pancreatic ductal adenocarcinoma

Results of a new clinical trial show that patients with resected pancreatic ductal adenocarcinoma treated with a modified FOLFIRINOX (mF) regimen had longer survival than those treated with gemcitabine. A total of 493 patients were randomly allocated to either treatment for 24 weeks. At 33.6 months median follow-up, median disease-free survival was 21.6 months and 12.8 months (P < 0.001) and 3-year disease-free survival was 39.7% and 21.4% in the mF group and the gemcitabine group, respectively. Median overall survival was 54.4 months and 35.0 months (P = 0.003) and 3-year overall survival was 63.4% and 48.6% in the mF group and the gemcitabine group, respectively. 75.9% in the mF group and 52.9% in the gemcitabine group experienced grade 3 or 4 adverse events.

References

Original article

  1. Conroy, T. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N. Engl. J. Med. 379, 2395–2406 (2018)

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Clemens Thoma.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Thoma, C. Modified FOLFIRINOX superior to gemcitabine in resected pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol 16, 140 (2019). https://doi.org/10.1038/s41575-019-0112-3

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing